港股異動丨合生創展集團高開2.64% 已回購4.97億港元股份,計劃更多回購
格隆匯12月10日丨合生創展集團高開2.64%,報17.08港元,總市值407億港元。合生創展集團發佈公吿,根據購回授權,公司獲許購回不超過約2.19億股股份。於該公吿日期,公司已根據購回授權購回合共1883.84萬股。有關購回股份的總代價約為4.97億港元(不包括佣金及開支)。有關購回股份,其中公司已註銷1324.63萬股購回股份及將予註銷559.21萬股購回股份,分別相當於公司現有已發行股份總數的約0.56%及0.23%。故董事會擬繼續行使其於購回授權項下的權力以購回公司股份。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.